Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands.
Repligen Corporation
Unlock to Claim this listing
Add / Modify Company
4.3
Overall Excellence Rating
Industry
HealthcareCategory
Medical Instruments & SuppliesESG/Ethical Impact
Repligen’s environmental impact is magnified by its commitment to sustainable manufacturing processes and resource conservation. Through energy-efficient technologies, waste reduction initiatives, and environmentally conscious supply chain practices, the company underscores its dedication to minimizing its carbon footprint. Repligen’s efforts to reduce water consumption, lower greenhouse gas emissions, and optimize resource usage showcase its commitment to environmentally responsible operations, contributing to a greener and more sustainable life sciences industry.Repligen’s social impact revolves around its mission to improve patient outcomes and enable scientific advancements. By developing critical bioprocessing technologies and solutions, the company plays an instrumental role in advancing scientific research and biopharmaceutical manufacturing. Additionally, Repligen’s commitment to promoting diversity, fostering employee development, and community engagement underscores its dedication to fostering positive societal change.Strong governance and ethical practices are the bedrock of Repligen’s operations. The company adheres to rigorous standards of compliance, transparency, and ethical decision-making. Transparent communication about its products, corporate practices, and ethical considerations underscores Repligen’s commitment to responsible governance, maintaining stakeholder trust, and upholding the highest ethical standards.Repligen’s financial sustainability is intricately linked to its commitment to innovation. The company’s investment in research and development drives advancements in bioprocessing technologies, contributing to scientific breakthroughs and improved manufacturing practices. By embracing strategic financial management and fostering innovation, Repligen maintains long-term value creation while driving the evolution of the life sciences field.Repligen’s ethical responsibility extends to its bioprocessing solutions and technologies. The company places quality assurance, regulatory compliance, and ethical manufacturing at the forefront of its operations. By maintaining stringent standards in its bioprocessing products, Repligen ensures ethical practices that contribute to the overall integrity of the life sciences industry.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Awards Received
2023
Revenues
$800,000,000.00
Website Traffic
Employee Rating
3.5
Customer Rating
2.7
Company Size
100-1000
ESG Risk Rating
4